These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33128347)

  • 21. Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kataoka H; Tomita T; Nakanowatari M; Kondo M; Mukai M
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):444-447. PubMed ID: 36972244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage.
    Chalkia A; Flossmann O; Jones R; Nair JR; Simpson T; Smith R; Willcocks L; Jayne D
    Nephrol Dial Transplant; 2024 Aug; 39(9):1473-1482. PubMed ID: 38268434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avacopan for the treatment of ANCA-associated vasculitis: an update.
    Osman M; Cohen Tervaert JW; Pagnoux C
    Expert Rev Clin Immunol; 2023 May; 19(5):461-471. PubMed ID: 36545762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
    Miao S; Suso P; Furst JA; Hudson MG; Trivedi A
    Clin Pharmacol Drug Dev; 2024 Sep; 13(9):1000-1010. PubMed ID: 38993026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AVACOPAN: A New Adjunctive Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Garg J; Frishman WH
    Cardiol Rev; 2023 Jan-Feb 01; 31(1):3-6. PubMed ID: 36469359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avacopan's potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis.
    Taniguchi T; Hiwa R; Shoji M; Yamaguchi E; Shirakashi M; Onizawa H; Tsuji H; Kitagori K; Nakashima R; Akizuki S; Onishi A; Yoshifuji H; Tanaka M; Morinobu A
    Mod Rheumatol Case Rep; 2024 Jul; 8(2):314-317. PubMed ID: 38564324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
    Cortazar FB; Muhsin SA; Pendergraft WF; Wallace ZS; Dunbar C; Laliberte K; Niles JL
    Kidney Int Rep; 2018 Mar; 3(2):394-402. PubMed ID: 29725643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement Inhibition in ANCA-Associated Vasculitis.
    Tesar V; Hruskova Z
    Front Immunol; 2022; 13():888816. PubMed ID: 35880179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Diffuse Alveolar Hemorrhage With Avacopan.
    Falde SD; Lal A; Cartin-Ceba R; Mertz LE; Fervenza FC; Zand L; Koster MJ; Warrington KJ; Lee AS; Aslam N; Abril A; Specks U
    ACR Open Rheumatol; 2024 Jul; ():. PubMed ID: 39077977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype.
    Terrier B; Jayne DRW; Hellmich B; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Akuthota P; Khoury P; Baylis L; Wechsler ME;
    ACR Open Rheumatol; 2023 Jul; 5(7):354-363. PubMed ID: 37312233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avacopan: First Approval.
    Lee A
    Drugs; 2022 Jan; 82(1):79-85. PubMed ID: 34826105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avacopan for the treatment of ANCA-associated vasculitis.
    Osman M; Cohen Tervaert JW; Pagnoux C
    Expert Rev Clin Immunol; 2021 Jul; 17(7):717-726. PubMed ID: 34006155
    [No Abstract]   [Full Text] [Related]  

  • 37. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
    de Groot K; Harper L; Jayne DR; Flores Suarez LF; Gregorini G; Gross WL; Luqmani R; Pusey CD; Rasmussen N; Sinico RA; Tesar V; Vanhille P; Westman K; Savage CO;
    Ann Intern Med; 2009 May; 150(10):670-80. PubMed ID: 19451574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of Glucocorticoids Concomitant With Avacopan and Subsequent Liver Injury in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Uchida T; Fukui S; Iwamoto N; Umetsu A; Okamoto M; Fujikawa K; Mizokami A; Tomokawa T; Hara K; Horai Y; Kawakami A
    J Rheumatol; 2024 Sep; ():. PubMed ID: 39147418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.